CTX-471 Combination

CTX-471 is a fully human monoclonal antibody that binds and activates a novel epitope of the co-stimulatory receptor CD137, also known as 4-1BB, a member of the tumor necrosis factor receptor superfamily.

In preclinical combination sudies, CTX-471 significantly enhances the efficacy of other IO agents including tumor targeting antibodies cetuximab (Erbitux) and trastuzumab (Herceptin), checkpoint inhibitors against PD-1 and PD-L1, and small molecule inhibitors of CXCR2.